Sirna Therapeutics licenses seminal RNA interference technology.Sirna Therapeutics Sirna Therapeutics Inc. (NYSE: RNAI), Sirna develops therapeutics based on RNA interference (RNAi) technology, a new and extremely potent method of using nucleic acids as drugs. , Inc. (Boulder, CO) has entered into a worldwide license agreement with the University of Massachusetts Medical School UMMS is ranked fourth in primary care education among the nation’s 125 medical schools in the 2006 U.S.News & World Report annual guide, “America’s Best Graduate Schools”. UMMS is also a major center for research. (Worcester, MA) for its undivided interest undivided interest n. title to real property held by two or more persons without specifying the interests of each party by percentage or description of a portion of the real estate. in the seminal intellectual property on RNA interference RNA interference
A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. (RNAi) technology covering short interfering RNA RNA: see nucleic acid.
in full ribonucleic acid
One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic (siRNA). This license significantly strengthens Sirna's broad RNAi intellectual property portfolio for the development of RNAi therapeutics.
The license covers the RNAi technology patent application filed by Tuschl, et al., International PCT (Private Communications Technology) A protocol from Microsoft that provides secure transactions over the Web. See security protocol. Publication WO 01/75164, which was jointly developed and is owned by the University of Massachusetts Medical School, Max-Planck Institute, Whitehead Institute Founded in 1982, the Whitehead Institute for Biomedical Research is a non-profit research and teaching institution located in Cambridge, Massachusetts. The Whitehead Institute was founded as a fiscally independent entity from Massachusetts Institute of Technology, and its members and the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, . The subject matter of this intellectual property includes the demonstration that short pieces of RNA, or siRNAs, could be engineered to inhibit gene expression in mammalian cells. This license grants Sirna Therapeutics rights to the undivided interest of the Medical School in the Tuschl et al., intellectual property for uses relating to relating to relate prep → concernant
relating to relate prep → bezüglich +gen, mit Bezug auf +acc human and veterinary therapeutic, prophylactic, diagnostic and health care applications.
Under the terms of the license agreement, the Medical School will receive licensing fees in cash and common stock from the company. The Medical School may receive additional cash and common stock from the company following the achievement of certain milestones. The Medical School may also receive royalties on commercial product sales covered by the licensed patents. Sirna Therapeutics and the Medical School will share in any revenues generated from the sublicensing of this patent.
"Sirna's license to this intellectual property from the University of Massachusetts Medical School significantly enhances our role as a leader in the field of RNAi," said Howard W. Robin, President and Chief Executive Officer of Sirna Therapeutics. "The Medical School has made outstanding contributions to the field and we look forward to collaborating with its researchers to advance RNAi technology. To ensure that the field of RNAi develops to its fullest potential, we plan to broadly offer sublicenses to this intellectual property."
"We are pleased to grant this license to Sirna Therapeutics, who is clearly the leader in the field of RNAi," said John L. Sullivan For the U.S. Secretary of the Navy, see John L. Sullivan (U.S. Navy). For others, see John Sullivan (disambiguation).
John Lawrence Sullivan (October 15 1858 – February 2 1918) was recognized as a Heavyweight Champion of Boxing from February 7 1882 to 1892. , MD, Director of the Office of Research at the University of Massachusetts Medical School. "The use of siRNAs provides significant opportunity to address important unmet medical needs. Sirna's impressive scientific, technical and development expertise makes them an ideal partner to realize the potential of RNAi. The Medical School is committed to advancing exciting scientific breakthroughs through industry leaders such as Sirna Therapeutics. We are also pleased to be working with a partner committing both its wide resources as well as a willingness to further sublicense this intellectual property to achieve the maximum opportunities for the development of therapeutic advances consistent with our mission as an academic health science center."
RNA interference (RNAi) is a mechanism used by cells to regulate the expression of genes and replication of viruses. The RNA interference mechanism uses siRNAs that induce the destruction of target RNA using naturally occurring cellular protein machinery. Harnessing the natural phenomenon of RNA interference holds potential for the development of a new class of drugs with specificity toward a wide range of diseases that result from undesirable protein production or viral replication. Sirna Therapeutics has exclusive rights to over 30 issued or allowed patents on RNA stabilization chemistry, delivery, process development, and manufacturing. Additionally, Sirna Therapeutics has filed over 50 patent applications covering various aspects of the RNAi technology developed internally, including targeting of mammalian and viral genes, siRNA stabilization chemistry, delivery, process development, and manufacturing.
Sirna believes that the Tuschl et al., intellectual property licensed from the Medical School reinforces its broad and enabling position in the field of RNAi and, together with Sirna's issued, licensed and pending RNAi patent portfolio covering numerous therapeutic targets and chemistries, gives Sirna the leading intellectual property position in the field.
Sirna is a biotechnology company leveraging its expertise in nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. technology to develop and commercialize products that target human diseases. Sirna Therapeutics' primary focus is to develop therapeutics based on a nucleic acid technology called ribonucleic acid Ribonucleic acid (RNA)
One of the two major classes of nucleic acid, mainly involved in translating into proteins the genetic information that is carried in deoxyribonucleic acid (DNA). interference, or RNAi
The University of Massachusetts Medical School, one of the fastest growing medical schools in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. Comprising the Graduate School of Nursing and the Graduate School of Biomedical Sciences Graduate School of Biomedical Sciences may refer to:
UMMS University of Maryland Medical System
UMMS United Methodist Missionary Society attracts more than $143 million in research funding annually, which enables UMMS researchers to explore human disease from the molecular level to large-scale clinical trials. Basic and clinical research leads to new approaches for diagnosis, treatment and prevention of disease.
Sirna Therapeutics, Inc.